Alnylam Pharmaceuticals | ALNY - Koszty Operacyjne





Koszty Operacyjne Zmiana Data
Acadia Pharmaceuticals USD 270.57M 450K 2026-09
Agios Pharmaceuticals USD 155.3M 24.53M 2026-06
Alnylam Pharmaceuticals USD 1.11B 52.78M 2026-09
Amgen USD 5.69B 6B 2026-09
Arrowhead Research USD 245.35M 30.35M 2026-06
BioCryst Pharmaceuticals USD -397.38M 517.17M 2026-09
BioMarin Pharmaceutical USD 819.04M 5.5B 2026-09
Incyte USD 5.64B 4.67B 2026-09
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
Moderna USD 1.18B 223M 2026-09
Neurocrine Biosciences USD 779.7M 40.6M 2026-09
Novartis USD 13.19B 3.9B 2026-09
PTC Therapeutics USD 211.54M 15.12M 2026-06
Regeneron Pharmaceuticals USD 33.5B 1.79B 2026-09
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 9.92B 941M 2026-06
Sarepta Therapeutics USD 390.39M 2.43M 2026-09
Takeda JPY 981.78B 36.71B 2026-09
Tectonic Therapeutic USD 24.22M 3.08M 2026-06
Ultragenyx Pharmaceutical USD 283M 6M 2026-09
Vertex Pharmaceuticals USD 2.18B 118.2M 2026-09
Xencor USD 87.82M 5.44M 2026-06